REFERENCES
1. Strand DS, Kim D and Peura DA. 25 years of proton pump inhibitors: a
comprehensive review. Gut Liver 2017; 11: 27-37.
2. Ying J, Li LC, Wu CY, Yu ZW and Kan LD. The status of proton pump
inhibitor use: a prescription survey of 45 hospitals in China. Rev Esp
Enfer Dig 2019; 111: 738-743.
3. Pasina L, Novella A, Elli C, Nobili A and Ianes A. Overuse of proton
pump inhibitors in nursing homes: an Italian multicenter observational
study. Pharmacoepidemiol Drug Saf 2020; 29: 461-466.
4. Haastrup PF, Thompson W, Søndergaard J and Jarbøl DE. Side effects of
long-term proton pump inhibitor use: a review. Basic Clin Pharm Toxicol
2018; 123: 114-121.
5. Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M and Vega KJ.
Potential proton pump inhibitor-related adverse effects. Ann N Y Acad
Sci 2020; https://doi.org/10.1111/nyas.14428.
6. Rameau A, Andreadis K, Bayoumi A, Kaufman M and Belafsky P. Side
effects of proton pump inhibitors: what are patients’ concerns? J Voice
2020; https://doi.org/10.1016/j.jvoice.2020.01.018.
7. Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P and
Savarino E. Latest insights into the hot question of proton pump
inhibitor safety - a narrative review. Dig Liver Dis 2020; 52: 842-852.
8. Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al.
The proton-pump inhibitor lansoprazole enhances amyloid beta production.
PLoS One 2013; 8: e58837.
9. Lam JR, Schneider JL, Zhao W and Corley DA. Proton pump inhibitor and
histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama
2013; 310: 2435-42.
10. Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG and Bhuiyan MA.
Cognitive impact after short-term exposure to different proton pump
inhibitors: assessment using CANTAB software. Alzheimer’s Research &
Therapy 2015; 7: 79.
11. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al.
Risk of dementia in elderly patients with the use of proton pump
inhibitors. European Archives of Psychiatry & Clinical Neuroscience
2015; 265: 419-28.
12. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al.
Association of Proton Pump Inhibitors With Risk of Dementia: A
Pharmacoepidemiological Claims Data Analysis. JAMA Neurology 2016; 73:
410-6.
13. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of
dementia from proton pump inhibitor use in Asian population: A
nationwide cohort study in Taiwan. PLoS ONE [Electronic Resource]
2017; 12: e0171006.
14. Batchelor R, Gilmartin JF, Kemp W, Hopper I and Liew D. Dementia,
cognitive impairment and proton pump inhibitor therapy: A systematic
review. Journal of Gastroenterology & Hepatology 2017; 32: 1426-1435.
15. Chen LY, Lin HJ, Wu WT, Chen YC, Chen CL, Kao J, et al. Clinical Use
of Acid Suppressants and Risk of Dementia in the Elderly: A
Pharmaco-Epidemiological Cohort Study. International Journal of
Environmental Research & Public Health [Electronic Resource] 2020;
17: 09.
16. Zhang Y, Liang M, Sun C, Song EJ, Cheng C, Shi T, et al. Proton pump
inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur
J Clin Pharmacol 2020; 76: 139-147.
17. Cooksey R, Kennedy J, Dennis MS, Escott-Price V, Lyons RA, Seaborne
M, et al. Proton pump inhibitors and dementia risk: Evidence from a
cohort study using linked routinely collected national health data in
Wales, UK. PLoS ONE [Electronic Resource] 2020; 15: e0237676.
18. Wu CL, Lei WY, Wang JS, Lin CE, Chen CL and Wen SH. Acid
suppressants use and the risk of dementia: A population-based propensity
score-matched cohort study. PLoS ONE [Electronic Resource] 2020; 15:
e0242975.
19. Park SK, Nam JH, Lee H, Chung H, Lee EK and Shin JY. Beyond
uncertainty: Negative findings for the association between the use of
proton pump inhibitors and risk of dementia. Journal of Gastroenterology
& Hepatology 2019; 34: 2135-2143.
20. Gray SL, Walker RL, Dublin S, Yu O, Aiello Bowles EJ, Anderson ML,
et al. Proton Pump Inhibitor Use and Dementia Risk: Prospective
Population-Based Study. Journal of the American Geriatrics Society 2018;
66: 247-253.
21. Wod M, Hallas J, Andersen K, Garcia Rodriguez LA, Christensen K and
Gaist D. Lack of Association Between Proton Pump Inhibitor Use and
Cognitive Decline. Clinical Gastroenterology & Hepatology 2018; 16:
681-689.
22. Lai SW and Liao KF. Association Between Proton Pump Inhibitors Use
and Dementia Risk. American Journal of Gastroenterology 2020; 115: 631.
23. Huang ST, Tseng LY, Chen LK, Peng LN and Hsiao FY. Does Long-Term
Proton Pump Inhibitor Use Increase Risk of Dementia? Not Really! Results
of the Group-Based Trajectory Analysis. Clinical Pharmacology &
Therapeutics 2019; 106: 616-622.
24. Kumar R, Kumar A, Nordberg A, Langstrom B and Darreh-Shori T. Proton
pump inhibitors act with unprecedented potencies as inhibitors of the
acetylcholine biosynthesizing enzyme-A plausible missing link for their
association with incidence of dementia. Alzheimer’s & Dementia 2020;
16: 1031-1042.
25. FDA. Data mining at FDA: white paper [on-line]. Available at
https://www.fda.gov/science-research/data-mining/data-mining-fda-white-paper
Accessed January 28, 2021.
26. Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, et
al. Use of data mining at the Food and Drug Administration. J Am Med
Inform Assoc 2016; 23: 428-434.
27. Evans SJ, Waller PC and Davis S. Use of proportional reporting
ratios (PRRs) for signal generation from spontaneous adverse drug
reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-486.
28. FDA. FDA adverse event reporting system (FAERS) quarterly data
extract files [on-line]. Available at
https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html Accessed
January 28, 2021.
29. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR and Denny JC.
MedEx: a medication information extraction system for clinical
narratives. Journal of the American Medical Informatics Association
2010; 17: 19-24.
30. Wu B, Wu FB, Luo M, Qin Z and Xu T. Application of MedEx in FAERS
drug names standardization. China J of Hosp Pharm 2019; 39: 1989-1992.
31. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R and
Egberts AC. A comparison of measures of disproportionality for signal
detection in spontaneous reporting systems for adverse drug reactions.
Pharmacoepidemiol Drug Saf 2002; 11: 3-10.
32. Evans SJ, Waller PC and Davis S. Use of proportional reporting
ratios (PRRs) for signal generation from spontaneous adverse drug
reaction reports. Pharmacoepidemiology & Drug Safety 2001; 10: 483-6.
33. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et
al. Association Between Proton Pump Inhibitor Use and Cognitive Function
in Women. Gastroenterology 2017; 153: 971-979.e4.
34. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J and
Hartikainen S. No Association Between Proton Pump Inhibitor Use and Risk
of Alzheimer’s Disease. American Journal of Gastroenterology 2017; 112:
1802-1808.
35. Palleria C, Leporini C, Chimirri S, Marrazzo G, Sacchetta S, Bruno
L, et al. Limitations and obstacles of the spontaneous adverse drugs
reactions reporting: Two ”challenging” case reports. J Pharmacol
Pharmacother 2013; 4: S66-72.